Show simple item record

dc.contributor.authorPranjol, MZI
dc.contributor.authorGutowski, NJ
dc.contributor.authorHannemann, M
dc.contributor.authorWhatmore, JL
dc.date.accessioned2018-11-08T13:28:22Z
dc.date.issued2018-08-31
dc.description.abstractBACKGROUND: Metastasis still remains the major cause of therapeutic failure, poor prognosis and high mortality in epithelial ovarian cancer (EOC) patients. Previously, we showed that EOC cells secrete a range of factors with potential pro-angiogenic activity, in disease-relevant human microvascular omental endothelial cells (HOMECs), including the lysosomal protease cathepsin L (CathL). Thus, the aim of this study was to examine potential pro-proliferative and pro-migratory effects of CathL in HOMECs and the activated signalling pathways, and whether these proangiogenic responses are dependent on CathL-catalytic activity. METHODS: HOMECs proliferation was investigated using WST-1, BrdU and CyQUANT assays. Cell migration was examined using a Cultrex Cell 96 transwell migration assay. A range of pHs were assayed to assess enzyme activity in the presence of CathL-specific fluorogenic substrate FY-CHO. Activation of cell signalling pathways was tested using commercially available phosphokinase array and intact cell-based ELISAs. RESULTS: We show for the first time that CathL has a potent pro-proliferative and pro-migratory effect on HOMECs. For instance, CathL significantly increases HOMEC proliferation (134.8±14.7% vs control 100%) and migration (146.6±17.3% vs control 100%). Our data strongly suggests that these proangiogenic effects of CathL are mediated via a non-proteolytic manner. Finally, we show that CathL-induced activation of the ERK1/2 pathway is involved in inducing these cellular effects in HOMECs. CONCLUSION: These data suggest that CathL acts as an extracellular ligand and plays an important pro-angiogenic, and thus pro-metastatic, role during EOC metastasis to the omentum, by activating the omental microvasculature, and thus can potentially be targeted therapeutically in the future.en_GB
dc.description.sponsorshipThis project was funded by FORCE Cancer Charity, Devon (Grant 50703, Charity registration no. 1140676)en_GB
dc.identifier.citationPublished online 31 August 2018en_GB
dc.identifier.doi10.2174/1568009618666180831123951
dc.identifier.urihttp://hdl.handle.net/10871/34676
dc.language.isoenen_GB
dc.publisherBentham Science Publishersen_GB
dc.relation.urlhttps://www.ncbi.nlm.nih.gov/pubmed/30173647en_GB
dc.rights.embargoreasonUnder embargo until 31 August 2019 in compliance with publisher policyen_GB
dc.rights© 2018 Bentham Science Publishersen_GB
dc.subjectangiogenesisen_GB
dc.subjectcathepsin Len_GB
dc.subjectmigrationen_GB
dc.subjectnon-proteolyticen_GB
dc.subjectproliferationen_GB
dc.titleCathepsin L induces proangiogenic changes in human omental microvascular endothelial cells via activation of the ERK1/2 pathwayen_GB
dc.typeArticleen_GB
exeter.place-of-publicationNetherlandsen_GB
dc.descriptionThis is the author accepted manuscript. The final version is available from Bentham Science Publishers via the DOI in this recorden_GB
dc.identifier.journalCurrent Cancer Drug Targetsen_GB


Files in this item

This item appears in the following Collection(s)

Show simple item record